22q11 Deletion Syndrome: Unlocking the Mystery of Psychosis Vulnerability
"Is there a link between this genetic anomaly and increased risk? Neurological soft signs reveal potential insights."
The 22q11 microdeletion syndrome (22q11DS), also known as velo-cardio-facial syndrome or Di George Syndrome, is a neurogenetic disorder impacting roughly 1 in every 4,000 live births. This condition arises from a missing piece of chromosome 22 and is a multisystemic disorder, leading to a wide range of congenital issues from facial differences and heart defects to immune deficiencies.
Adding to the complexity, 22q11DS is often associated with neurocognitive challenges, including intellectual disabilities, learning differences (particularly in math), and difficulties with visuospatial skills, attention, and executive functions. Moreover, a significant number of individuals with 22q11DS experience psychiatric disorders, most notably attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, mood disorders, and schizophrenia spectrum disorders. Compared to the general population, those with 22q11DS face a dramatically increased risk of psychosis.
Given these factors, recent research has investigated a potential connection between ‘neurological soft signs’ (NSSs) and 22q11DS. Neurological soft signs are subtle motor, sensory, or integrative abnormalities that, while not indicative of specific brain lesions, may point to broader neurodevelopmental differences. Studies suggest that these signs could act as markers of vulnerability to schizophrenia. Thus, exploring the presence and nature of NSS in individuals with 22q11DS could further our understanding of the syndrome’s link to psychosis.
Prevalence and Vulnerability
Psychotic disorders affect an estimated 25–35% of individuals with 22q11.2 Deletion Syndrome by young adulthood. Another review reports that about 25% develop schizophrenia, while approximately 1% of patients with schizophrenia have 22q11.2 deletion syndrome. The syndrome is therefore viewed as a neurogenetic model for studying psychosis risk in the broader population. Neurological soft signs, including overflow movements, dysrhythmia, and reduced speed on timed activities, are considered markers of vulnerability to schizophrenia.
A Prospective Research Model
Researchers use 22q11.2 Deletion Syndrome as a model for prospective studies of how psychosis emerges. Its defined genetic risk can support investigations of gene–environment interactions and genome–phenome associations. However, robust and replicable functional brain signatures of 22q11.2DS and its associated psychosis remain elusive. Longitudinal evaluation of psychosis-spectrum features is therefore an important part of current research.
Neurological Soft Signs: What Do They Tell Us?
Neurological soft signs (NSS) encompass minor motor, sensory, and coordination-related features that don't fit neatly into specific diagnostic boxes but can indicate underlying neurological differences. Common NSS include:
- Overflow Movements: Involuntary movements in body parts not directly involved in a task.
- Dysrhythmia: Irregularities in the rhythm or timing of movements.
- Difficulties with Timed Activities: Challenges in performing tasks within a specific time frame, such as rapidly alternating hand movements.
Expanding the Evidence Base
Recent work continues to examine the clinical and cognitive profile of 22q11.2 Deletion Syndrome. A 2026 review emphasizes pathophysiological pathways, clinical management, diagnosis, and future research directions. Another 2026 systematic review analyzed 37 articles on the neuropsychological profile of individuals with 22q11.2 deletion syndrome using PRISMA and COSMIN methodologies. Research on early-onset psychosis also distinguishes psychosis beginning before 18 years of age.
Limits of Neurological Soft Signs
Neurological soft signs have been proposed as independent markers of vulnerability to psychosis in 22q11 microdeletion syndrome. In the reported study, both the 22q11 clinical group and the ultra-high-risk group showed more neurological soft signs than healthy controls. However, the two clinical groups did not differ in the number of neurological soft signs. This finding limits the ability of the measure to distinguish these particular clinical risk groups.
Heterogeneous Outcomes
Comparative studies examine 22q11.2 deletion syndrome alongside nondeleted individuals across comorbidities, functioning, cognition, and psychosis features. The largest study described in the source was intended to cover the full range of overall severity. A separate account highlights substantial phenotypic heterogeneity despite identical hemizygous deletions spanning approximately 46 genes. That account reports that only 25–40% of individuals develop psychotic disorders, underscoring that the deletion alone does not determine outcome.
Implications and Future Directions
This research highlights the significance of neurological soft signs as potential markers of atypical neurodevelopment in individuals with 22q11DS and those at ultra-high risk for psychosis. While NSS do not appear to directly correlate with specific positive or negative symptoms, their presence may indicate an underlying vulnerability to psychosis independent of psychopathology. Longitudinal studies with larger samples are needed to fully understand the predictive value of NSS and to clarify their relationship with specific brain circuits.
Beyond the Deletion
Evidence from the International 22q11.2 Deletion Syndrome Brain and Behavior Consortium suggests that chromosomal microdeletions are significantly more likely to involve protein-coding genes. The same source reports that several rare copy number variants are associated with psychosis in individuals who carry the deletion. These findings support a model in which additional genomic variation may help explain why psychosis develops in some deleted individuals but not others.
Immune and Brain Pathways
A case-based report discusses immune findings in 22q11.2 deletion syndrome and psychosis. It states that higher IL-17 levels were found in patients with fewer symptoms and highlights the roles of Th17 and IL-17 in hippocampal development and psychosis. The report also describes a high IL-6/IL-10 ratio favoring a pro-inflammatory state in those patients. Separately, a deep neural network-based multi-cohort study investigated functional brain signatures of 22q11.2 deletion syndrome and associated psychosis.